13155-56-1

Upstream product

• 64-18-6 formic acid 
• 1193-47-1 2,2-dimethyl-cyclohexanone 
• 99440-28-5 (6,6-dimethyl-1-cyclohexen-1-yl)methanol 
• 99992-39-9 ethyl 2,2-dimethylcyclohexanecarboxylate 
• 408318-16-1 ethyl 6,6-dimethylcyclohex-1-enecarboxylate 
• 2979-10-4 ethyl 2,2-dimethyl-6-oxocyclohexane-1-carboxylate 
• 1257045-68-3 ethyl {6,6-dimethyl-2-(trifluoromethanesulfonyloxy)cyclohexene-1-yl}carboxylate 
• 583-60-8 2-Methylcyclohexanone 
• 13149-23-0 1-Aethoxymethyl-2,2-dimethyl-cyclohexanol-⁽¹⁾ 

Downstream Products

• 13155-63-0 1-<2,2-Dimethyl-cyclohex-1-yl>-but-1-en-3-on 
• 62581-18-4 2,2-dimethylcyclohexanecarboxylic acid 
• 1416557-25-9 (2,2-dimethylcyclohexyl)(4-fluorophenyl)methanone 
• 1416557-26-0 (R)-((R)-2,2-dimethylcyclohexyl)(4-fluorophenyl)methanol 
• 1441168-83-7 N-((2,2-dimethylcyclohexyl)methyl)-3-fluoroaniline 
• 1441167-97-0 N-((2,2-dimethylcyclohexyl)methyl)-3-fluoroaniline hydrochloride 
• 1441168-85-9 N-((2,2-dimethylcyclohexyl)methyl)-3-fluoro-N-methylaniline 
• 1441167-99-2 N-((2,2-dimethylcyclohexyl)methyl)-3-fluoro-N-methylaniline hydrochloride 

Relevant academic research and scientific papers

OPSIN-BINDING LIGANDS, COMPOSITIONS AND METHODS OF USE

Compounds and compositions are disclosed that are useful for treating ophthalmic conditions caused by or related to production of toxic visual cycle products that accumulate in the eye, such as dry adult macular degeneration, as well as conditions caused by or related to the misfolding of mutant opsin proteins and/or the mis-localization of opsin proteins. Compositions of these compounds alone or in combination with other therapeutic agents are also described, along with therapeutic methods of using such compounds and/or compositions. Methods of synthesizing such agents are also disclosed.

OPSIN-BINDING LIGANDS, COMPOSITIONS AND METHODS OF USE

Compounds are disclosed that are useful for treating ophthalmic conditions caused by or related to production of toxic visual cycle products that accumulate in the eye, such as dry adult macular degeneration, as well as conditions caused by or related to the misfolding of mutant opsin proteins and/or the mis-localization of opsin proteins. Compositions of these compounds alone or in combination with other therapeutic agents are also described, along with therapeutic methods of using such compounds and/or compositions. Methods of synthesizing such agents are also disclosed.

Synthesis of aldehydes by a one-carbon homologation of ketones and aldehydes via --α,β-unsaturated isocyanides

Ketones and aldehydes react via a Wittig-Horner-Emmons reaction using diethyl(isocyanomethyl)phosphonate to form α,β-unsaturated isocyanides (4), which are either hydrolyzed as such, under acid conditions, or hydrolyzed after oxidation to α,β-unsaturated isocyanates (6) to give aldehydes containing one additional carbon atom.The scope of the reaction is demonstrated by 20 examples.